Cancers de la sphère ORL : l’immunothérapie donne de la voix ! [Head and neck cancer : promising results of immunotherapy]

Détails

ID Serval
serval:BIB_FFCBF161F44F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Cancers de la sphère ORL : l’immunothérapie donne de la voix ! [Head and neck cancer : promising results of immunotherapy]
Périodique
Revue medicale suisse
Auteur(s)
Sivade A., Bensaid D., Monnier Y., Shabafrouz K., Bouchaab H., Cristina V.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
17/05/2017
Peer-reviewed
Oui
Volume
13
Numéro
563
Pages
1029-1031
Langue
français
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Immunotherapy, especially checkpoint inhibitors such as anti-PD1 and anti-PDL1 antibodies, has changed the standard of care and the prognosis of melanoma, but also more recently of lung cancer, renal cancer and Hodgkin lymphoma. Results of preliminary studies in head and neck squamous cell carcinoma (HNSCC) as well as in less frequent tumors of the region, such as nasopharyngeal carcinoma and high grade salivary gland carcinoma, are also promising. Indeed, in a recent phase 3 study, the PD1 inhibitor nivolumab has recently demonstrated a significant improvement in overall survival for platin-resistant recurrent and/or metastatic HNSCC.
Mots-clé
Carcinoma/pathology, Carcinoma/therapy, Carcinoma, Squamous Cell/pathology, Carcinoma, Squamous Cell/therapy, Head and Neck Neoplasms/pathology, Head and Neck Neoplasms/therapy, Humans, Immunotherapy/methods, Immunotherapy/trends, Melanoma/pathology, Melanoma/therapy, Nasopharyngeal Neoplasms/pathology, Nasopharyngeal Neoplasms/therapy
Pubmed
Création de la notice
22/06/2017 20:21
Dernière modification de la notice
20/08/2019 16:30
Données d'usage